NCT05666128
Completed
Phase 2
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Hyundai Pharm1 site in 1 country112 target enrollmentJune 17, 2022
Overview
- Phase
- Phase 2
- Intervention
- HD-6277
- Conditions
- Type 2 Diabetes Mellitus
- Sponsor
- Hyundai Pharm
- Enrollment
- 112
- Locations
- 1
- Primary Endpoint
- Change in HbA1c(%) at weeks 12 from baseline
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 6 weeks prior to screening.
Exclusion Criteria
- •Type 1 diabetes or another immune-mediated diabetes syndrome
Arms & Interventions
HD-6277 100mg
Intervention: HD-6277
HD-6277 50mg
Intervention: HD-6277
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Change in HbA1c(%) at weeks 12 from baseline
Time Frame: at weeks 12 from baseline
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Tezepelumab COPD Exacerbation StudyChronic Obstructive Pulmonary Disease (COPD)NCT04039113AstraZeneca337
Unknown
Phase 2
A Study of TG103 Injection in Overweight or ObesityOverweight or ObesityNCT05299697CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.195
Completed
Phase 2
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)Atopic DermatitisNCT04530643Shaperon80
Completed
Phase 2
XC8 in the Treatment of Patients With Bronchial AsthmaBronchial AsthmaNCT03450434PHARMENTERPRISES LLC120
Completed
Phase 2
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)AsthmaBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesNCT03688074AstraZeneca116